US · LAB · MEDICAL - EQUIPMENT & SERVICES
Standard BioTools Inc. (LAB) intrinsic value and stock valuation
$0.63as of 2026-11-21 · Mkt cap 313.17M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Standard BioTools Inc. DCF and intrinsic value
InvestorsCraft values LAB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LAB’s statements →
Standard BioTools Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $85.3M | $174.4M | $106.3M | $98M | $130.6M |
| Operating income | -$-93.31M | -$-175.24M | -$-76.6M | -$-116.2M | -$-67.46M |
| Net income | -$-74.9M | -$-138.88M | -$-74.66M | -$-190.1M | -$-59.24M |
| EPSd | -$-196.27K | -$-393.8K | -$-943.15K | -$-2.43M | -$-781.63K |
| Operating cash flow | -$-74.35M | -$-143.45M | -$-43.29M | -$-89.37M | -$-44.06M |
| Capital expenditure | -$-8.3M | -$-8.36M | -$-2.83M | -$-3.83M | -$-13.26M |
| Free cash flow | -$-82.65M | -$-151.81M | -$-46.12M | -$-93.19M | -$-57.33M |
| Total assets | $567.8M | $612.3M | $323.1M | $390.3M | $275.2M |
| Total debt | $30.8M | $33M | $98.2M | $102.7M | $111.7M |
| Net debt | -$-87.39M | -$-133.73M | $46.5M | $21.4M | $83.2M |
| Total equity | $424.3M | $471.7M | -$-148.05M | -$-81.47M | $94.6M |
| Cash and short-term investments | $187.6M | $292.9M | $114.9M | $165.8M | $28.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $85.3M | $174.4M | $106.3M | $98M | $130.6M |
| Cost of revenue | $42.8M | $90.2M | $55.9M | $60.9M | $61.2M |
| Gross profit | $42.5M | $84.3M | $50.5M | $37.1M | $69.4M |
| Research and development expenses | $26M | $62.4M | $26M | $37.4M | $37.9M |
| Selling, general and administrative expenses | $109.9M | $156.6M | $87.5M | $102.3M | $98.9M |
| Other expenses | $0.00 | $40.5M | $13.6M | $13.6M | $0.00 |
| Operating expenses | $135.9M | $259.5M | $127.1M | $153.3M | $136.8M |
| Cost and expenses | $178.6M | $349.7M | $182.9M | $214.2M | $198M |
| Interest income | $9.18M | $20.2M | $5.57M | $2.23M | $0.00 |
| Interest expense | $30K | $3.32M | $4.57M | $4.33M | $3.82M |
| Depreciation and amortization | $6.98M | $16.9M | $15.2M | $15M | $15.6M |
| Ebitda | -$-89.69M | -$-118.14M | -$-54.46M | -$-173.57M | -$-44.27M |
| Operating income | -$-93.31M | -$-175.24M | -$-76.6M | -$-116.2M | -$-67.46M |
| Total other income/expenses, net | -$-3.4M | $36.9M | $2.4M | -$-76.72M | $3.8M |
| Income before tax | -$-96.7M | -$-138.31M | -$-74.2M | -$-192.93M | -$-63.66M |
| Income tax expense | -$-37.88M | $570K | $450K | -$-2.83M | -$-4.42M |
| Net income | -$-74.9M | -$-138.88M | -$-74.66M | -$-190.1M | -$-59.24M |
| Weighted average shares outstanding | $381.6M | $352.7M | $79.2M | $78.3M | $75.8M |
| Weighted average diluted shares outstanding | $381.6M | $352.7M | $79.2M | $78.3M | $75.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $187.6M | $292.9M | $114.9M | $165.8M | $28.5M |
| Net receivables | $13.4M | $33.6M | $19.7M | $17.3M | $18.3M |
| Inventory | $20M | $40.7M | $20.5M | $21.5M | $20.8M |
| Total current assets | $454.3M | $375.9M | $158.2M | $208.8M | $72.1M |
| Property, plant and equipment, net | $46M | $71.4M | $54.9M | $59.5M | $65.2M |
| Goodwill and intangible assets | $0.00 | $140.3M | $107.7M | $118.9M | $134.3M |
| Long-term investments | $25.7M | $0.00 | $0.00 | $0.00 | $1M |
| Total non-current assets | $113.5M | $236.5M | $164.9M | $181.5M | $203.2M |
| Total assets | $567.8M | $612.3M | $323.1M | $390.3M | $275.2M |
| Accounts payable | $5.41M | $12.3M | $9.24M | $7.91M | $10.6M |
| Short-term debt | $5.49M | $6.23M | $63.9M | $5.76M | $9.89M |
| Deferred revenue | $39M | $18.6M | $16.7M | $14.4M | $15.5M |
| Total current liabilities | $108.3M | $65.9M | $109.3M | $43.4M | $49.6M |
| Long-term debt | $25.3M | $26.8M | $34.4M | $96.9M | $101.8M |
| Deferred revenue, non-current | $7.79M | $39.9M | $14.3M | $18.2M | $24.1M |
| Total non-current liabilities | $35.2M | $74.7M | $361.8M | $428.3M | $131.1M |
| Capital lease obligations | $25M | $32.7M | $34.7M | $37.8M | $40.6M |
| Total liabilities | $143.5M | $140.6M | $471.1M | $471.8M | $180.6M |
| Common stock | $400K | $400K | $80K | $80K | $80K |
| Retained earnings | -$-1.26B | -$-1.19B | -$-1B | -$-926.1M | -$-736M |
| Accumulated other comprehensive income (loss) | -$-1.49M | $1.23M | -$-2.22M | -$-1.9M | -$-910K |
| Total equity | $424.3M | $471.7M | -$-148.05M | -$-81.47M | $94.6M |
| Total investments | $95.1M | $126.2M | $63.2M | $84.5M | $1M |
| Total debt | $30.8M | $33M | $98.2M | $102.7M | $111.7M |
| Net debt | -$-87.39M | -$-133.73M | $46.5M | $21.4M | $83.2M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-74.9M | -$-138.88M | -$-74.66M | -$-190.1M | -$-59.24M |
| Depreciation and amortization | $1.72M | $16.9M | $15.2M | $15M | $16.2M |
| Stock-based compensation | $29.6M | $31.7M | $13.1M | $14.9M | $16.1M |
| Change in working capital | -$-44.98M | -$-12.08M | $1.79M | -$-12.35M | -$-18.01M |
| Accounts receivable | -$-1.36M | $8.97M | -$-2.99M | $1.06M | $6.73M |
| Inventory | -$-11.52M | -$-9.88M | -$-4.91M | -$-8.47M | -$-4.78M |
| Accounts payable | $2.44M | $0.00 | $1.62M | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-74.35M | -$-143.45M | -$-43.29M | -$-89.37M | -$-44.06M |
| Investments in property, plant and equipment | -$-8.3M | -$-8.36M | -$-2.83M | -$-3.83M | -$-13.26M |
| Acquisitions, net | $0.00 | $278.7M | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $24.8M | $363.2M | $20.2M | -$-88.13M | -$-11.95M |
| Common stock issued | $1.05M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | -$-40.95M | -$-5.41M | -$-770K | -$-1.79M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $570K | -$-102.62M | -$-6.81M | $230.8M | $16M |
| Net change in cash | -$-48.17M | $116.3M | -$-29.82M | $52.9M | -$-40.07M |
| Cash at end of period | $120.7M | $168.8M | $52.5M | $82.3M | $29.5M |
| Operating cash flow | -$-74.35M | -$-143.45M | -$-43.29M | -$-89.37M | -$-44.06M |
| Capital expenditure | -$-8.3M | -$-8.36M | -$-2.83M | -$-3.83M | -$-13.26M |
| Free cash flow | -$-82.65M | -$-151.81M | -$-46.12M | -$-93.19M | -$-57.33M |
Line items
Line items
Line items
About Standard BioTools Inc.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
- CEO
- Michael Egholm
- Employees
- 389
- Beta
- 1.42
Explore
Frequently asked questions
What is the intrinsic value of Standard BioTools Inc. (LAB)?
InvestorsCraft does not currently publish an intrinsic value for LAB. How the IC value is calculated.
Is LAB undervalued?
InvestorsCraft does not publish an undervaluation signal for LAB at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.